Lorelei Mucci

Related Links

Biography

My major area of research and teaching is cancer epidemiology. I am the Director of the Cancer Epidemiology and Cancer Prevention Program (Area of Interest) within the Department of Epidemiology here at the Harvard T.H. Chan School of Public Health (HSPH). In addition, I am Leader of the Cancer Epidemiology Program at the Dana-Farber/Harvard Cancer Center.

After receiving my doctoral degree in epidemiology at the Harvard T.H. Chan School of Public Health (formerly the Harvard School of Public Health), I trained as a post-doctoral fellow in cancer epidemiology at the Karolinska Institutet, Sweden. At the Karolinska, I gained expertise in using nationwide health registries to examine cancer etiology and formed a long-term partnership with epidemiology colleagues in the Nordic countries. For the past 9 years, my primary faculty appointment has been at the Harvard Chan School, where my research uses integrative molecular epidemiology approaches within cohorts in the United States and globally to investigate research questions focused on cancer etiology, mortality, and survivorship. I serve as co-Principal Investigator for the Health Professionals Follow-up Study (https://sites.sph.harvard.edu/hpfs/) as well as IRONMAN (see below). Below is a summary of some major areas of interest.

Publications

• Reply to "Letter to the editor: Incidence of de novo malignancy and all-cause mortality among heart transplant recipients".

  Barrera Flores FJ, Mostofsky E, Salia S, Lehman L, Liou L, Mucci L, Mittleman MA. Int J Cardiol 2025 Jan 15

• A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer.

  Srinivasan S, Kryza T, Bock N, Tse BWC, Sokolowski KA, Janaththani P, Fernando A, Moya L, Stephens C, Dong Y, Röhl J, Alinezhad S, Vela I, Perry-Keene JL, Buzacott K, Nica R, Gago-Dominguez M, Schleutker J, Maier C, Muir K, Tangen CM, Gronberg H, Pashayan N, Albanes D, Wolk A, Stanford JL, Berndt SI, Mucci LA, Koutros S, Cussenot O, Sorensen KD, Grindedal EM, Travis RC, Haiman CA, MacInnis RJ, Vega A, Wiklund F, Neal DE, Kogevinas M, Penney KL, Nordestgaard BG, Brenner H, John EM, Gamulin M, Claessens F, Melander O, Dahlin A, Stattin P, Hallmans G, Häggström C, Johansson R, Thysell E, Rönn AC, Li W, Brown N, Dimeski G, Shepherd B, Dadaev T, Brook MN, Spurdle AB, Stenman UH, Koistinen H, Kote-Jarai Z, Klein RJ, Lilja H, Ecker RC, Eeles R, Clements J, Batra J. Nat Commun 2024 Nov 06

• What's in a Name? Why Words Matter in Advanced Prostate Cancer.

  Oh WK, Agarwal N, Bryce A, Barata P, Bugler C, Carlsson SV, Cornell B, Dahut W, George D, Loeb S, Montgomery B, Morris D, Mucci LA, Omlin A, Palapattu G, Riaz IB, Ryan C, Schoen MW, Washington SL, Gillessen S. Eur Urol 2024 Oct 28

• Germline DNA damage repair variants and prognosis of patients with high-risk or metastatic prostate cancer.

  Stopsack KH, Vijai J, Conry M, Berchuck JE, Kemel Y, Vasselman SE, Freeman DA, Lee GM, Mandelker D, Solit DB, Morris MJ, Penney KL, Abida W, Offit K, Mucci LA, Kantoff PW, Pomerantz MM. Clin Cancer Res 2024 Oct 25

• Intratumoral vitamin D signaling and lethal prostate cancer.

  Vaselkiv JB, Shui IM, Grob ST, Ericsson CI, Giovannucci I, Peng C, Finn SP, Mucci LA, Penney KL, Stopsack KH. Carcinogenesis 2024 Oct 10